340B Optimization & Compliance
Increasing regulatory scrutiny and shrinking margins make early 340B visibility a leadership imperative.
The Leadership Challenge
340B programs are becoming more complex, more scrutinized, and more financially significant. Many leaders lack early visibility into compliance risk and margin erosion until audits or policy changes force action.
Why the Risk Is Hard to See Early
340B data is often siloed across pharmacy systems, split-billing software, and compliance tools. Regulatory changes move faster than internal reporting structures, leaving leadership reactive rather than prepared.
What Happens If It’s Ignored
- Lost savings from preventable inefficiencies
- Increased audit exposure
- Compliance risk that threatens program sustainability
- Leadership uncertainty around expansion decisions
How Cura Intervenes
Cura provides advisory support across 340B strategy, compliance, and optimization. We help leadership understand where risk exists, how margin is impacted, and what governance structures are required to sustain the program long-term.
What Changes for Leadership
- Earlier visibility into compliance and margin risk
- Stronger confidence during audits and regulatory shifts
- Clearer guidance for program expansion and partnerships
- Improved alignment between finance, pharmacy, and leadership
Representative Outcomes
- Reduced compliance exposure
- Improved program transparency
- More informed expansion and contracting decisions
Case Illustration
A health center navigating evolving 340B regulations partnered with Cura to assess governance and reporting gaps. Leadership gained clarity on compliance posture and implemented changes before regulatory pressure escalated.
